She is among many patients now asking why, with no apparent change in their blood test results, chronic kidney disease (CKD) is suddenly appearing as a problem on their medical charts. The answer is ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

Mineralys Therapeutics announced positive topline results from its phase 2 Explore-CKD trial, in which lorundrostat lowered ...

Investigators studied apixaban pharmacokinetics, pharmacodynamics, and hemorrhage risk by kidney function. Kidney function is a major predictor of hemorrhage among patients with atrial fibrillation ...

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

We randomly assigned participants with chronic kidney disease (estimated glomerular filtration rate [eGFR], 30 to 90 ml per minute per 1.73 m 2 of body-surface area), albuminuria (a urinary ...

High blood pressure, also known as Hypertension, is a chronic, most life-long, irreversible condition in which the force of ...

Kidney failure, a silent killer, often goes unnoticed as the body adapts, masking symptoms like fatigue and swelling. The ...

It’s important for clinicians to assess patients undergoing percutaneous coronary intervention (PCI) for both anemia and chronic kidney disease (CKD).

A biomarker panel can improve prediction of chronic kidney disease (CKD) progression in children, according to a study ...

More information: Rajiv Agarwal et al, Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2410659 ...

Looking at pooled trial data on over 23,000 patients with type 2 diabetes, heart failure, or chronic kidney disease (CKD), empagliflozin was associated with a lower risk of a 50% or greater ...